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Approximately one-third of hepatitis C- (HCV)
infected persons in the United States passed
through jail or prison facilities in 1997.1 In some
states, the prevalence of chronic HCV infection
among incoming prisoners is as high as 49%
(see Table 1). Correctional healthcare providers
are on the front line in the diagnosis and man-
agement of HCV in this country.
Among those with chronic HCV, the natural his-
tory of progression from infection to cirrhosis in
an individual patient is uncertain. Ten to 15 per-
cent of those with HCV will develop cirrhosis
within 20 years of initial infection.6,7 Studies eval-
uating serial liver biopsies in HCV-infected pris-
oners have demonstrated distinct cohorts of fast,
moderate, and non-progressors.8 Numerous
studies have demonstrated that coinfection with
HIV increases the rate of progression to cirrho-
sis. 
Chronic liver disease and cirrhosis kills more
than 25,000 people in the US annually9 and is
among the 10 leading causes of death for White
males, Hispanics, and Native Americans.10 In
patients with HCV and cirrhosis, the five-year
death rate is approximately 15%.11 In some cor-
rectional facilities, end-stage liver disease
(ESLD) is now the leading cause of death among
inmates.12 This article focuses on the treatment
of ESLD in the correctional setting, primarily
among patients with chronic HCV.
Chronic Hepatitis Treatment -
Some Patients Left Behind?
Advances in combination therapy have improved
clinical options for some patients with chronic
HCV.  However, correctional health providers are
still confronted with many patients with cirrhosis
and ESLD.  Reasons for this include:
(1) Even under ideal treatment conditions, sus-
tained viral response (SVR) rates for the current
anti-HCV combination therapy (pegylated inter-
feron plus ribavirin) are less than 50% for geno-
type 1, and less than 80% for other less common
genotypes.13
(2) Many people cannot tolerate anti-HCV com-
bination therapy because of side effects, co-mor-
bidities (including psychiatric issues), or other
factors.
(3) Prisoners are eight to 10 times more likely
than the general population to be HIV-infected.14
Coinfection with HIV is estimated to reduce SVR
rates for anti-HCV combination therapy by 20 to
30%, though some of this difference may be due
to adherence issues.15 As highly active antiretro-
viral therapy (HAART) has reduced HIV-related
morbidity and mortality among HIV-infected per-
sons, ESLD has risen in importance as a cause
of death among people with HIV/AIDS16 (see
Table 2).
(4) Prisoners in the US are disproportionately
African American, and HCV treatment response
rates are lower among African Americans than
among other racial groups.  This treatment dis-
parity has not been adequately explained, and is
now the subject of a major federal study.18
(5) Some correctional healthcare systems do not
routinely offer HCV testing or treatment for
inmates.  The number of such systems is expect-
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TABLE 1: Proportion of persons 
ntering state prisons found to have 
HCV infection
WOMEN MEN
California:2 39% 32%
Maryland:3 39% 25%
Massachusetts:4 44% 27%
Texas:5 49% 27%
ed to decline now that the Centers for
Disease Control and Prevention (CDC) has
published guidelines for managing viral
hepatitis in correctional settings.19
Diagnosis of Viral Hepatitis
and Cirrhosis
The first step in the diagnosis of liver dis-
ease due to viral hepatitis is to offer antibody
screening for hepatitis B and C (HBV, HCV).
Some clinicians recommend targeted
screening based upon risk factor histories.
In many correctional systems, the preva-
lence of chronic hepatitis among inmates is
sufficiently high and the reliability of risk fac-
tor history information is sufficiently low that
all inmates should be offered testing for both
viruses.   
Most of those infected with HBV will sponta-
neously clear the virus and be left with anti-
bodies to the viral surface and core anti-
gens.  Approximately 5% will develop chron-
ic HBV.  Unlike HBV infection, 60-85% of
those with HCV infection will develop chron-
ic disease.20 Chronic infection with HCV can
be confirmed by detection of HCV RNA in
the plasma. 
Among those with chronic viral hepatitis, no
single test or panel is sufficient to accurate-
ly portray disease severity. A basic lab
assessment for patients with liver disease
should include complete blood counts
(CBC), serum aminotransferase levels (ALT
and AST), bilirubin, albumin, prothrombin
time/INR, and platelet count. Serial mea-
surements over time offer a more complete
portrait of the severity progression of the dis-
ease than individual assays.  Elevated
AST/ALT values reflect inflammation, while
prolonged INR and decreased albumin can
reflect decreased hepatic function.  Elevated
direct bilirubin may be indicative of cirrhosis
or bile duct obstruction; total bilirubin levels
over approximately 2.5 mg/dl are associated
with jaundice. Anemia can be due to variceal
bleeding, while thrombocytopenia can result
from bleeding or sequestration in an
enlarged spleen.  
Physical examination of patients with
advanced liver disease may detect a firm
and enlarged liver, though in very advanced
cirrhosis, the liver may decrease in size.
External physical examination may also
detect excess fluid in the abdomen by pal-
pating the flanks and feeling for a shifting
wave of fluid.  Imaging techniques such as
ultrasound, CT scan, and MRI can reveal
ascites, an enlarged spleen, reversed portal
vein flow, and hepatocellular carcinoma
(HCC). 
Liver biopsy is the single best technique for
determining disease progression, and is the
definitive means of confirming cirrhosis and
assessing its severity.21 Liver biopsy has
become a contentious issue in corrections
because of cost and the high number of
patients with chronic viral hepatitis.  Despite
advances in noninvasive monitoring tech-
niques, biopsy remains the gold standard for
the assessment of severity of cirrhosis.22,23,24
Most of those with serially "normal" ALTs will
have minimal inflammation, are likely to be
to be slow progressors, and may not need to
undergo biopsy. Just as HCV treatment
costs may be reduced by price negotiation25,
it may be possible to reduce biopsy costs by
proactively contracting for biopsies based
on HCV prevalence in the facility or system
in question.  Correctional health providers in
Pennsylvania have reportedly reduced biop-
sy costs to as low as $400 per patient.26 A
the California Medical Facility in the
California DOC, on site biopsy costs are less
than $300 per patient.27
Pathophysiology and
Complications of Cirrhosis
Damage to the liver due to chronic alcohol
or other toxins, infection, obstruction, or
heart failure can lead pathologic changes
including fibrosis and the formation of regen-
erative nodules. These pathologic changes
are termed cirrhosis, and can result in a vari-
ety of clinical manifestations.  When the liver
is cirrhotic but still able to perform most
basic functions, cirrhosis is referred to as
"compensated". Further loss of functioning
hepatocytes can result in "decompensated"
cirrhosis, manifest by coagulopathy, jaun-
dice, and edema. Extensive fibrosis can
cause portal hypertension, splenomegaly,
and gastroesophageal varices.  In more
severe cases, patients may develop excess
fluid within the peritoneal cavity (ascites),
spontaneous bacterial peritonitis, and/or
encephalopathy.  Up to 5% of those with cir-
rhosis will develop HCC.  Deaths associated
with HCV are more likely to be due to com-
plications of decompensated cirrhosis such
as variceal bleeding, encephalopathy, and
peritonitis, than to HCC.28
Portal hypertension: When scar tissue
obstructs the normal flow of blood through
the liver, pressure within the liver's main
blood vessel, the portal vein, is increased.
Portal hypertension is responsible for com-
mon complications of ESLD, including
variceal bleeding and ascites.
Variceal bleeding:When blood cannot flow
normally through the portal vein, it must
return to the heart using other blood vessels.
These other blood vessels, called varices,
enlarge to provide an alternative pathway for
blood diverted from the liver. Varices often
form in the stomach and esophagus. They
pose a high risk for rupture and bleeding
ecause they are thin-walled, often abnor-
mally twisted and swollen, and subject to
high pressure. Internal variceal bleeding
occurs in 20 to 30% of cirrhotic patients and
is dangerous, with mortality rates reported
between 15 and 50%.29 Vomiting blood or
passing black stools can be signs of variceal
bleeding.
Ascites: Lowered albumin production from
the cirrhotic liver and other physiological
processes can result in fluid retention in the
peritoneal cavity.  Ascites itself is not life-
th eatening, but it is a marker of severe dis-
ase progression. The probability of death
within two years in cirrhotic patients hospi-
talized with ascites is approximately 40%,
and is worse for those who develop sponta-
n ous bacterial peritonitis (SBP), a common
and potentially fatal complication of
cites.30
Encephalopathy: The exact pathogenesis
of hepatic encephalopathy is not clear. A
build-up of toxins such as ammonia can
affect the brain, causing confusion, memory
loss, fatigue, agitation, and possibly coma
and death. Early symptoms of encephalopa-
thy can include confusion, drowsiness,
lethargy, and difficulty concentrating. The
physical examination in those with
encephalopathy may demonstrate tremor,
asterixis, and slowed coordination. 
Hepatorenal syndrome:Hepatorenal syn-
drome is a potentially life-threatening com-
plication of liver disease in which patients
2
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TABLE 2: Before and after HAART: ESLD as a cause of death in 
HIV-infected persons17
Setting Pre-HAART Era HAART Era
# / % Year # / % Year
Brescia, Italy 305/13% 1987 46/35% 1996
Madrid, Spain 312/5% 1991-5 20/45% 2000
Boston, MA (USA) 36/12% 1991 22/50% 1998-9
Paris, France 1327/2% 1995 543/8% 1997
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Dear Colleagues: 
I am reminded of the problems addressed in this issue of the HEPP Report every time I visit the
inpatient ward of my facility. Several of our ID clinic patients have become long-term residents of
that ward, simply because their liver disease cannot be safely managed in the outpatient corr c-
tional setting. I have had to revisit published literature in order to learn to manage these pati n s
more effectively. This issue of HEPP Report was conceived with that need for an update in i d
- we’ve now provided you (and me!) with the latest information on the management of inmates
presenting with chronic hepatitis and cirrhosis.
Unfortunately, HCV-related liver disease is only likely to become even more common in correc-
tional settings as time goes on. While the incidence of HCV (the rate of new infections) is slowly
decreasing, HCV-related liver disease is becoming more common as HCV infections "mature".
The prevalence of HCV-related liver disease is expected to peak in the year 2010 both inside and
outside of correctional settings. Given the fact that the cost for hospitalizations related to HCV in
the United States was 1.6 billion dollars in 1998, 10 to 12 years before the expected peak, it is
clear that we are about to witness a major shift in prison health care expenditures.
Given that potential scenario, aggressive treatment of HCV-infected patients in correctional envi-
ronments should be viewed as potentially cost saving. One decision analysis study  has demon-
strated that HCV treatment resulted in a net savings in the range of $400 to $3500 over the life-
time of each patient, in the same range of cost effectiveness as stool guiac testing, pneumococ-
cal vaccination, coronary bypass surgery, and mammography.  According to a more recent pub-
lication, combination HCV therapy resulted in improvements in Quality Adjusted Life Year (QALY)
for both men and women. QALY measures improvements in health-related quality of life, mean-
ing less chronic illness and fewer laboratory tests and clinic visits. These are the same types of
benefits that have been observed over the past 10 years following improvements in HIV care.
More aggressive management of HCV infection in the near term may therefore affect the "bottom
line" for correctional health care in years to come.
My visits to the inpatient ward in my facility hint at our collective future. We anticipate that this
issue of HEPP Report will provide you with an overview of prevention, diagnosis and treatment
of viral hepatitis and cirrhosis, and approaches that may be efficacious in preventing common
complications of end-stage liver disease.
And let us not forget to celebrate the season! The entire staff of HEPP Report wishes you a won-
derful holiday and a happy and healthy 2004!
Sincerely,
Annie De Groot, M.D, 
Co-chief Editor, HEPP Report
Letter from the Editor
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4develop oliguria, hyponatremia, hypoten-
sion, and renal failure manifest by increases
in BUN and creatinine. The exact etiology of
this syndrome is not clear, but it can be pre-
cipitated by sepsis, severe variceal bleeding,
aggressive diuresis or paracentesis.
Patients with advanced cirrhosis also com-
monly develop malnutrition, gallstones, and
coagulopathy due to impaired hepatic
synthesis of clotting factors and thrombocy-
topenia. 
Prevention and Treatment
of Complications
The prevention and treatment of complica-
tions associated with ESLD can be challeng-
ing for even experienced generalist physi-
cians. In general, the management of those
with ESLD should be done in consultation
with a gastroenterologist or hepatologist.  In
one recent study, hospitalized patients with
decompensated cirrhosis managed by a
generalist in consultation with a gastroen-
terologist fared better than patients man-
aged by generalists alone. Better outcomes
included shorter length of hospitalization,
lower cost of hospitalization, lower rates of
hospital readmission, and improved sur-
vival.31
Patients with chronic hepatitis should be
protected from further hepatic insult. Those
who are not immune to hepatitis A and
hepatitis B should be vaccinated.32 Those
with liver disease should receive annual
influenza vaccinations and a pneumococcal
vaccine. Patients should avoid hepatotoxic
medications whenever possible. Large
doses of acetominophen should be avoided,
however, low doses (less than 2,000 mil-
ligrams per day) are generally well-tolerated.
Non-steroidal anti-inflammatory drugs such
as ibuprofen (Advil®), naproxen (Aleve® or
Naprosyn®), or aspirin should be used with
caution both because of hepatotoxic poten-
tial and the risk for bleeding. The dosage of
medications that are hepatically metabolized
may need to be adjusted.  Because of the
increased prevalence of HIV infection
among those with viral hepatitis, patients
should also be encouraged to test for HIV. 
Alcohol
Because alcohol is commonly covertly man-
ufactured and ingested in prison, all patients
should be educated about the extreme
importance of avoiding alcohol.  Even mod-
erate ingestion of alcohol hastens the pro-
gression of liver disease in those with cirrho-
sis. Correctional physicians should link their
patients to drug and alcohol abuse treatment
programs both within the correctional sys-
tem and at the time of release. 
Nutrition
Maintaining adequate nutrition for patients
with advanced liver disease can be difficult
in the community, and poses particular chal-
lenges in the prison setting. Adequate
dietary protein is important for patients with
ascites and for repairing lost muscle mass.
However, excess protein may pose a risk for
encephalopathy. In those prone to
encephalopathy, vegetable proteins may
pose fewer risks than animal proteins.  Iron
supplementation and excessive sodium
intake should be avoided in those with cir-
rhosis.  Patients with ascites may require
fluid and salt restriction.
Variceal bleeding
Beta-blockers can reduce heart rate, lower
portal vein pressure, and reduce the threat
of variceal bleeding.  Patients with diabetes,
asthma, emphysema and chronic bronchitis
may be unable to tolerate beta-blockers.
Options for treatment of variceal bleeding
and prevention of recurrence also include
endoscopic scleropathy, vasoactive drugs,
and band ligation. Surgical shunts and
Transjugular Intrahepatic Portosystemic
Shunt (TIPS) are other options to eliminate
variceal bleeding. TIPS is a less invasive
procedure in which the shunt is inserted
through a catheter.
Ascites
Patients with ascites may require a reduced
salt diet, reduced fluid intake, and diuretics.
Spironolactone in doses of 100-400 mil-
ligrams per day can be used to achieve
diuresis. In those who fail to respond to
diuretics, fluid may be drained with a
catheter or plastic drainage tube inserted
into the abdominal wall (paracentesis).
Paracentesis should be accompanied by
albumin infusion to prevent circulatory dys-
function and other complications.33 TIPS is
also an option in ascites patients for whom
paracentesis is ineffective, intolerable, or
contraindicated.34
Bacterial Peritonitis
Patients with SBP may present with fever,
hypotension, abdominal discomfort, and/or
encephalopathy. Often the clinical findings
are very subtle, and the clinician must act
presumptively to prevent death of the
patient.  Gram stain and culture of ascitic
fluid often fails to demonstrate the presence
of an organism. To diagnose SBP, ascitic
fluid should be examined by microscope and
inoculated directly into blood culture bottles.
An ascitic fluid neutrophil count of 250 poly-
morphonuclear cells/mm3 is diagnostic of
SBP.30 In suspected cases, treatment should
be initiated with cefotaxime, ceftriaxone, or a
fluoroquinolone. Patients who have already
had a previous episode of SBP are at high
risk for recurrence, and should be provided
prophylaxis with trimethoprim -sulfamethox-
azole, ciprofloxacin, or norfloxacin.
Encephalopathy
Precipitating factors for encephalopathy in
advanced liver disease can include gastroin-
testinal bleeding, excess dietary protein,
constipation, or infection. The goal of treat-
ment for encephalopathy is to lower the level
of toxic substances affecting the brain by
reducing or eliminating dietary protein and
removing nitrogenous material from the gut,
often by using lactulose.35
Fulminant hepatic failure is manifest as
encephalopathy, worsening jaundice, gas-
trointestinal bleeding, sepsis, coagulopathy,
hypoglycemia, renal failure, and electrolyte
abnormalities. Patients with fulminant hepat-
ic failure should be managed in the ICU set-
ting, and should urgently be evaluated for
candidacy for liver transplant.36
Transplantation
More than 3,000 liver transplants are per-
formed annually in the US. For patients with
cirrhosis, the two commonly used indices of
liver disease severity are Child-Turcotte-
Pugh (CTP) and Model for End Stage Liver
Disease (MELD). CTP and MELD are
designed to direct organ allocation to liver
transplantation candidates based on the
Management of End
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Continued on page 5
December 2003     Volume 6, Issue 12visit HEPP Report online at www.hivcorrections.org
TABLE 3: 
Signs and Symptoms of Cirrhosis
Many patients with cirrhosis have no
symptoms, and are only determined to
be cirrhotic by physical examination
and liver biopsy. When signs or symp-
toms are present, they can include:
w enlargement of the liver
w loss of appetite
w unusual weight loss or weight gain
w nausea and vomiting
w fatigue
w jaundice
w enlargement of the spleen
w abdominal swelling
w swelling of the legs
w amenorrhea (absence of menstrual 
periods)
w intense itching
w vomiting blood
w palmar erythema (reddish and 
blotchy palms)
w loss of body hair
w spider angiomas (pinhead-sized red 
spots on the skin with tiny visible 
blood vessels, blanch with pressure)
5severity of disease. CTP score is deter-
mined using albumin, bilirubin, prothrombin
time (INR), ascites, and hepatic
encephalopathy.  MELD score is determined
using bilirubin, creatinine, and INR.  MELD
uses a wider range of assay values and a
more complicated formula than CTP. A
MELD calculator is available online at the
website of the United Network for Organ
Sharing: www.unos.org. Every correctional
system should have policies in place that
address the appropriate evaluation and
referral of selected patients for consideration
for transplant. 
Anti-HCV Maintenance Therapy
There is little clinical basis for recommenda-
tions about continued anti-HCV therapy in
patients with advanced cirrhosis.
Nevertheless, some studies have shown
that patients with compensated cirrhosis can
achieve high rates (43%) of SVR on combi-
nation therapy,37 and that anti-HCV therapy
may cause histological improvement even in
patients who are virological non-respon-
ders.38 Whether or not treatment of compen-
sated cirrhotics will translate into decreased
morbidity, improved quality of life, or pro-
longed survival remains to be seen. 
Anti-HCV treatment of patients with decom-
pensated cirrhosis may raise significant
safety issues and should not generally be
recommended except in the setting of clini-
cal trials.  
Hepatocellular Carcinoma (HCC)
Chronic HCV infection is a major risk factor
for HCC. The risk for HCC is greatest among
patients with at least 20 years of HCV infec-
tion, cirrhosis or advanced fibrosis, male
sex, older age, HBV coinfection, and heavy
alcohol use.39 One to 6% of cirrhotic patients
develop HCC annually.40 Screening tech-
niques for HCC in cirrhotic patients are
serum alpha-fetoprotein (AFP) testing (twice
yearly) and hepatic ultrasound or CT.
Surgical liver resection and liver transplant
are the main treatment strategies for HCC.
Alternative approaches include percuta-
neous alcohol injection, arterial chemoem-
bolization, or radiofrequency ablation.41
Palliative Care, Compassionate Release
Patients with ESLD, especially those who
are not candidates for liver transplantation,
should be considered for hospice care and
compassionate parole or release. Patients
dying with ESLD report a high pain burden,
comparable to that of patients dying with
lung and colon cancer.42 Physicians working
with such patients should be aware of avail-
able palliative care options, and should initi-
ate compassionate release or medical
parole proceedings where appropriate. 
Conclusions
Over the past 20 years, correctional health-
care providers have become increasingly
important in our nation's response to tuber-
culosis and HIV.  With one-third of HCV-
infected individuals in the US passing
through our jails and prisons, correctional
clinicians are now faced with a new chal-
lenge.  As we become experts in the antivi-
ral treatment of those with chronic hepatitis,
we must also be cognizant of the manage-
ment of those with ESLD.  By doing so, we
can decrease ESLD associated morbidity
and prolong the lives of our patients suffer-
ing with this serious illness.
Management of End
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Dosing of pegylated interferon for the treatment of hepatitis C infection
Pegasys® (pegylated  interferon alfa-2a) and CopegusTM (Ribavirin, USP) dosing recommendations
HCV Genotype
1 or 4
2 or 3
Pegasys Dose
180 µg subcutaneously once a
week
180 µg subcutaneously once a
week
Copegus Dose
<75 kg: 1000 mg daily in two
divided doses  
>75 kg: 1200 mg daily in two
divided doses 
800 mg daily in two divided
doses 
Duration
48 weeks
24 weeks
PEG-IntronTM (pegylated interferon alfa-2b) monotherapy dosing recommendations
The recommended dose of PEG-IntronTM regimen is 1.0 µg/kg/week for one year. The volume of PEG-Intron to be
injected depends on the vile strength used and the patient’s weight. (See table below)
PEG-IntronTM (pegylated interferon alfa-2b) and Rebetol® (Ribavirin, USP) dosing recommendations
When administered in combination with Rebetol®, the recommended dose of PEG-IntronTM is 1.5 µg/kg/week. The volume
of PEG-IntronTM to be injected depends on the vile strength used and the patient’s weight. The recommended dose of
Rebetol® is 800 mg/day in two divided doses. (See table below)
Body weight (kg)
<45 
46-56
57-72
73-88
89-106
107-136
137-160
PEG-Intron vial strength
50 µg per 0.5 mL 
80 µg per 0.5 mL 
120 µg per 0.5 mL
150 µg per 0.5 mL 
Amount of PEG-Intron (µg)
to administer
40
50
64
80
96
120
150
Volume (mL)* of PEG-
Intron to administer
0.4
0.5
0.4
0.5
0.4
0.5
0.5
Body weight (kg)
<40
40-50
51-60
61-75
76-85
>85
PEG-Intron vial strength
50 µg per 0.5 mL
80 µg per 0.5 mL
120 µg per 0.5 mL
150 µg per 0.5 mL 
Amount of PEG-Intron (µg)
to administer
50 
64 
80 
96 
120 
150 
Volume (mL)* of PEG-
Intron to administer
0.5
0.4
0.5
0.4
0.5
0.5
*When reconstituted as directed
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Infections caused by methicillin resistant Staphylococcus aureus
(MRSA) have long been a problem in hospitals and nursing homes.
Over the past decade, MRSA has also emerged as a cause of skin
and soft tissue infections in the community.1 Not surprisingly, this
organism is now being increasingly recognized as a cause of infec-
tions in residents of jails and prisons.2,3,4 This article summarizes
basic concepts of MRSA diagnosis and management and reviews
recent experiences with MRSA in the correctional environment. 
Staphylococcus aureus(SA)
Staphylococcus aureus(SA) is a bacterium commonly found on the
skin or in the nose of healthy individuals.  Although it is often a col-
onizer causing no disease, it can be responsible for minor to life-
threatening infections of the skin, bone, blood, heart valves, and
lungs.  SA is easily spread by contact with the skin of a person infect-
ed or colonized with the bacteria. SA can also be acquired from inan-
imate objects that have been in contact with a person carrying the
organism.  
Methicillin resistant Staphylococcus aureus(MRSA)
Penicillin resistance in SA is due to the production of beta lacta-
mase, an enzyme that breaks down penicillin's beta lactam ring and
renders the drug inactive.  Within a few years of the first clinical use
of penicillin in the 1940s, resistance due to beta lactamases was
identified. Within a year of the introduction of the semisynthetic, beta
lactamase-stable, penicillin methicillin in 1960, MRSA strains were
identified. By the 1990s, over half of SA isolated in some hospitals
were MRSA.  Nursing homes and other long-term care facilities have
been identified as reservoirs. Risk factors for infection with MRSA
include prolonged hospitalization, having been in an intensive care
unit, contact with other patients who have MRSA, having had
surgery or another invasive procedure, injection drug use, and
underlying illnesses such as diabetes. 
Many microorganisms that develop high-level resistance pay a com-
petitive price to carry that antibiotic resistance and are less fit.
However, MRSA appears to be as virulent in its resistant form as it
is in its wild type.  Most MRSA infections are minor infections of the
skin that take the form of pustules, furuncles or boils.  Generally,
these conditions are mild and self-limited.  It is not always necessary
to treat every infection aggressively. 
Methicillin resistant strains are resistant to all beta lactam antibiotics,
including penicillins and cephalosporins.  In addition, MRSA strains
often carry plasmids that lead to resistance to multiple other antibi-
otics.  Many MRSA strains are susceptible to trimethoprim-sul-
famethoxazole and rifampin. Virtually all SA are fully susceptible to
vancomycin. However, the first clinical isolate of SA with reduced
susceptibility to vancomycin was reported from Japan in 1996.5 The
first documented case of infection caused by vancomycin-resistant
S. aureus(VRSA) (vancomycin MIC >32 µg/mL) in a patient in the
United States was reported in 2002.6
Is it just a spider bite?
In the correctional setting, there has been significant amount of mis-
information on the "inmate grapevine" that attributes these otherwise
unremarkable lesions to arachnid bites.  In reality, spiders rarely bite
people, and most of the bites are inconsequential. Most spiders only
bite when provoked such as when they are trapped in clothing or in
a shoe. Spider bites characteristically occur at areas where the spi-
der might settle in the clothing, such as the waistband. It is unusual
for a spider to bite multiple times.  
The brown recluse spider, or Loxosceles reclusa, in particular, has
b en blamed for lesions among the incarcerated. Found in the
Midwest and Southeast, this arachnid prefers isolated areas and is
rather shy and timid. It hibernates during the winter, so bites, which
ar  generally painless, occur between March and October. Following
a bite, the skin may exhibit a urticarial lesion (hive), a papule, or a
pustule. In severe reactions, patients may develop systemic signs
including rash, fever, headache, and other flu-like symptoms. Only a
small proportion of bites become necrotic, and the progression fol-
lows a characteristic pattern termed the "red, white, and blue" sign:
a central blister with purple-gray discoloration (in Caucasians), sur-
rounded by a white ring of blanched skin and a much larger halo of
red. If skin breakdown occurs, the site becomes painful, usually pro-
gressing to a black eschar and may be slow to heal.
The misinterpretation of minor skin lesions as spider bites has ironi-
cally led to actions that potentially increase health risks for many
inmates. The use of chemicals to eradicate the falsely accused spi-
ders only serves to eliminate an ally in the war against mosquitoes,
which are known to carry illnesses such as West Nile virus. 
Recent MRSA outbreaks
Outbreaks of MRSA infections are being increasingly recognized in
jails and prisons throughout the country.2,3,4 Factors that may have
ontributed to the problem include: limited access to soap or bathing,
m ntal illness among prisoners leading to poor hygiene,  inadequate
laundry procedures, co-payments for medical care which may limit
acc ss to medical care, infrequent collection of wound cultures, and
the misperception that lesions were due to spider bites. 
Georgia: In 2001 and 2002, the Georgia Division of Public Health,
the Georgia Department of Corrections, and local health depart-
ments investigated outbreaks of MRSA skin infections in three cor-
rectional facilities.  Risk factors identified included prolonged incar-
ceration, previous antimicrobial use, self-draining of boils, skin lac-
erat on (intentional or accidental), washing clothes by hand, and
sharing soap.  Beta lactam antibiotics were not uncommonly used,
even after the identification of MRSA.  A number of measures were
implemented, with limited success. These included wide spread
screening for skin disease, implementation of standardized antimi-
crobial treatment recommendations, changes in laundry practices,
inmate education, the use of chlorhexidine containing soaps, and the
use of alcohol-based hand rubs. 
Los Angeles: In 2002, the Los Angeles (L.A.) County jail experi-
enced an increase in reports of spider bites. In response, a protocol
was initiated that called for culturing all suspected spider bite
lesions. Between January of 2002 and June of 2003, over 1,600
MRSA skin infections were identified. In collaboration with the L.A.
Cou ty Department of Health Services, the jail recommended
c anges to include enhanced skin lesion surveillance, standardized
treatment protocols including empiric treatment with non-beta-lac-
tam antimicrobials for all wound infections, inmate hygiene educa-
tion, environmental cleaning, and more frequent laundry changes.
Texa : In 1996, the Texas Department of Criminal Justice (TDCJ)
implemented a comprehensive set of treatment and prevention
guidelines for MRSA skin infections that included 1) surveillance, 2)
hygiene education for inmates, 3) access to proper wound care, 4)
standardized antimicrobial therapy based on drug susceptibility data
(including directly observed therapy), 5) early treatment of skin dis-
Lou Tripoli*, M.D. and Joseph Bick**, M.D.
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ease, and 6) eradication of MRSA from asymptomatic carriers who
have recurrent MRSA infections. Since 1998, TDCJ has required cul-
turing of all draining skin lesions and reporting of results to the TDCJ
Office of Preventive Medicine. The proportion of SA infections that
were methicillin-resistant increased from 24% (864 of 3,520) in 1998
to 66% (5,684 of 8,633) in 2002. Implementation of guidelines and a
continued multidisciplinary approach to MRSA infections has not led
to substantial decreases in the incidence of MRSA.
Mississippi: An evaluation of MRSA cases at a state prison in
Mississippi revealed that 19 of 21 (90%) of infected inmates with
wound dressings changed their dressings themselves. Fifteen (33%)
of infected inmates reported helping or being helped by other
inmates with wound care or dressing changes. Twenty-six (58%)
reported lancing their own boils or other inmates' boils with finger-
nails or tweezers; forty (89%) shared personal items (e.g., linen, pil-
lows, clothing, and tweezers) that potentially were contaminated by
a wound. 
Treatment of MRSA infections
Some correctional systems have developed guidelines for the man-
agement of  MRSA. In July 2003, the federal Bureau of Prisons
issued guidelines to prevent and control MRSA in correctional facili-
ties7. This document recommends the reporting and tracking of
patients with MRSA and offers a convenient form to do so.  In addi-
tion, a useful patient education handout can be found at the end of
the document.
Facilities detecting a substantial number of MRSA infections should
implement improved hygiene, infection-control, and treatment prac-
tices. Skin lesions should be cultured to determine the infecting
organism. Drainage of abscesses is important to facilitate cure.
Empiric antibiotic selection should be made with MRSA in mind.
Treatment should be adjusted as needed based upon the infecting
organism's antibiotic susceptibility pattern. 
Trimethoprim-sulfamethoxazole (Bactrim, Septra) in a dose of one
double-strength tablet twice daily is usually effective in patients who
have MRSA. Some clinicians also add rifampin in a dose of 600 mg
once daily. Due to the rapid development of resistance, rifampin
should not usually be used alone to treat infections due to SA. For
more serious infections, intravenous vancomycin or oral linezolid
may be used. A new antibiotic, daptomycin, (Cubicin™) has recent-
ly been approved for treatment of skin infections due to SA.
Daptomycin is given parenterally, and has a spectrum of activity that
includes virtually all Gram-positive organisms including E. faecalis,
E. faecium(including VRE) and SA including MRSA. Daptomycin
should not be used for pneumonia due to higher failure in clinical tri-
als, and should not be relied upon for CNS or bone infections due to
poor penetration of these tissues. 
Clinicians are reminded that oral vancomycin is non-absorbable and
is, therefore, not useful in the treatment of skin and soft tissue infec-
tions due to SA. 
Eradication of nasal carriage
SA and MRSA commonly inhabit the anterior nares of otherwise
healthy asymptomatic individuals.  Routine eradication of this car-
riage is neither efficacious nor recommended. In some cases of
recurrent active disease, clearance of the organism from the nose
can be beneficial.  Mupirocin (Bactroban®) ointment, applied to both
anterior nares bid for 5-7 days, is commonly used for this purpose. 
Education and Infection Control
Inmates should be educated about personal hygiene, and advised to
avoid touching other persons' wounds or wound drainage.  Inmates
should be provided access to soap, showers, and sinks. Clinical staff
that provides wound care should follow Standard Precautions.
Infection control measures can never be overemphasized, as even in
the hospital setting many healthcare professionals neglect hand
washing. The restrooms in many hospitals and public settings are
poorly designed, leading people to re-contaminate their hands imme-
diately after washing them.  
In an effort to improve hand hygiene, the use of alcohol-containing
antiseptic scrubs is increasingly being encouraged. However, secu-
rity concerns may lead to these particular disinfectants not being uni-
versally embraced in the correctional setting.  Surfaces that are used
by multiple people should be routinely decontaminated. Laundry
should be washed in hot water for at least 25 minutes to be sure that
most bacteria have been exterminated.  Custody staff should be edu-
cated to refer inmates who have even minor-appearing skin infec-
tions so that an appropriate evaluation can be performed. 
The involvement of experts in infection control and infectious dis-
eases can be useful in both managing individual patients and estab-
lishing protocols specific to the unique needs of each facility. 
Correctional facilities experiencing outbreaks of MRSA should seek
assistance from their local and state health departments. MRSA out-
breaks can be reported to CDC (telephone [800] 893-0485) through
state departments of corrections and state health departments.
Preventing MRSA disease in inmates might be an important mea-
sure for preventing MRSA in the community outside the correctional
facility. Additional information about MRSA is available at
http://www.cdc.gov/ncidod/hip/aresist/mrsa.htm  
In conclusion, the recent experience with MRSA in jails and prisons
reminds us that antibiotic-resistant organisms will continue to be a
significant problem in this country. Lessons learned from the MRSA
experience may also be applicable to other infections to come.
Correctional healthcare providers' responsibility to public health can-
not be underestimated. It is important to strengthen our relationships
with outside public health agencies as we strive to contain this grow-
ing threat to the health of those patients entrusted to our care. 
Disclosures: *Nothing to disclose.
**Nothing to disclose.
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HIV Drug Resistance Testing: 
Utilizing phenotypic and geno-
typic tests to optimize therapy
December 18, 2003, 12p EST
This first online seminar in the
series will focus on the use of phe-
notypic and genotypic information
to manage drug resistance.
Visit: www.phenosense.com/mdr
The 11th Conference on
Retroviruses and 
Opportunistic Infection
February 8-11, 2004
San Francisco, California
Contact: Office of the Retrovirus
Conference Secretariat
Call: 703.535.6862
Fax: 703.535.6899
Email: info@retroconference.org
Visit: www.retroconference.org
Management of HIV/AIDS in 
the Correctional Setting:
A Live Satellite 
Videoconference Series
Albany Medical Center
March 16, 2004
12:30 PM - 3:30 PM EST
CME and Nursing credits available
Visit: www.amc.edu/Patient/hiv/
hivconf/index.htm 
Call: 518.262.4674 
Email: ybarraj@mail.amc.edu 
National HIV/AIDS 
Update Conference
March 27-30, 2004
Hyatt Regency Miami
Miami, Florida
Sponsored by American
Foundation for AIDS Research 
Email: jessica@fa-events.com
NCCHC: Clinical Updates in
Correctional Health Care
May 22-25, 2004
Hyatt Regency
Chicago, Illinois
Call: 773.880.1460
Fax: 773.880.2424
Visit: www.ncchc.org
9th Northeast Correctional
Health Care Conference
May 26, 2004
Sturbridge Host Hotel
Sturbridge, Massachusetts
Call: 781.279.2254
Fax: 781.279.2977
Email: rduhaime@icg-ps.com
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Magic Johnson visits California prison for
World AIDS Day
Continuing his commitment to reaching out to at-
risk populations, Earvin "Magic" Johnson visited
California Medical Facility in Vacaville, CA on
Dec. 3, 2003. After a private meeting with the
prison's inmate peer educators, Magic spoke to
an appreciative audience of over 600 inmates,
recounting his own personal journey following his
diagnosis with HIV in 1991. The audience
responded enthusiastically to Magic's messages
concerning  testing, treatment, and prevention.
Earlier in the week, the prison was host to
Assemblyman Mark Leno, Senator Gloria
Romero, and 35 members of the San Francisco
Gay Men's Chorus. Senator Romero took the
opportunity to call upon the CA DOC to evaluate
the feasibility of distributing condoms to inmates.
Study: Long Term Adefovir in HBeAg
Negative Chronic Hepatitis B Results in
Significant Virological, Biochemical, and
Histologic Improvement
This study presented from the Henry Dunant
Hospital, Athens, Greece and Gilead Sciences
showed that Adefovir dipivoxil (ADV) 10 mg has
demonstrated significant histological, virological,
and biochemical improvement as compared to
placebo (PLB) through 48 weeks of therapy in
HBeAg positive and HBeAg negative patients.
Study authors concluded that Adefovir for 96
weeks resulted in significant and continued
reduction in HBV DNA and ALT; and additional
histologic improvement beyond that seen at week
48. Discontinuation of ADV resulted in loss of
HBV DNA and ALT suppression and reversion of
histologic improvement. Emergence of adefovir
resistance was delayed and infrequent. Adefovir
has a distinct resistance profile from lamivudine. 
Marcellin, Patrick et al. 54th AASLD October
2003 Poster 1156.
Sexual Transmission of HCV in Heterosexual
Monogomous Couples 
The aim of this study is to determine the potential
for sexual transmission of HCV among monoga-
mous heterosexual couples by identifying the fac-
tors (sexual and non-sexual) associated with anti-
HCV positivity among partners, and the related-
ness of virus strains among concordant couples.
The prevalence of anti-HCV among sexual part-
ners of persons with HCV was 4% (95% CI:
2.3%-5.7%) but 40% of partners had discordant
types indicating lack of sexual transmission. The
majority of type concordant couples lacked per-
cutaneous risk factors for HCV, suggesting sex
may be the route of transmission but phylogenet-
ic analysis of viral strains will ultimately determine
whether sexual transmission occurred.
Terrault, NA et al. 54th AASLD. October 2003
Abstract 716.
Weight Loss and Exercise Can Improve
Fibrosis 
Obesity is a risk factor for the progression of
fibrosis in chronic liver diseases such as non-
alcoholic fatty liver disease (NAFLD) and hepati-
tis C (HCV). The aim of this study was to investi-
gate the longer-term effect of weight loss on liver
biochemistry, serum insulin levels and quality of
life in overweight patients with liver disease and
th  effect of subsequent weight maintenance or
regain and to determine factors associated with
successful weight maintenance. It was demon-
strated that lifestyle interventions reduced risk
factors associated with progression of liver dis-
ease, decreased abnormal liver enzymes,
improved quality of life and in a proportion of
pa ients improved histological features of liver
injury. Importantly, these changes were achiev-
able and sustainable with relatively small but per-
sistent changes in lifestyle. Treatment of over-
weight should form an important component of
the management of patients with chronic liver dis-
ease. 
Hickman, IJ et al. 54th AASLD. October 2003
Abstract 716.
Study: Survival of HIV-Infected Liver
Transplant Recipients
With immune function restoration made possible
by HAART (Highly Active Antiretroviral Therapy),
a study from the University of Pittsburgh evaluat-
ed 24 HIV positive subjects with ESLD who were
undergoing Orthotopic liver transplantation
(OLTX). In contrast to the finding of past inferior
survival observed among HIV-infected transplant
recipients, this study found that successful liver
transplantation is possible for HIV-infected sub-
jects, and that for HIV-infected subjects, post-
OLTX survival with ART is similar to that for HIV
negative subjects. Data from this study provide a
sc entific rationale to justify that HIV infection
should no longer be considered an absolute con-
traindication to transplantation, which is consis-
tent with recent transplantation arguments based
on ethical considerations.
Ragni, MV et al. Journal of Infectious Diseases
188 (2003) pp. 1412-1420.
Inside News
Resources
For more information on hepatitis: 
w www.hivandhepatitis.com/hiv_hcv_co_inf/
080403a.html
w www.cdc.gov/hepatitis
For more information on MRSA:
w www.cdc.gov/ncidod/hip/aresist/mrsa.htm
w www.ojp.usdoj.gov/bjs/prisons.htm
Immunization questions?
w Email nipinfo@cdc.gov
w Call CDC's Immunization Information Hotline
at (800) 232-2522
w Call your state health dept., (phone numbers
at: www.immunize.org/coordinators)
December 2003     Volume 6, Issue 12visit HEPP Report online at www.hivcorrections.org
Self-Assessment Test for Continuing Medical Education Credit
Brown Medical School designates this educational activity for 1 hour in category 1 credit toward the AMA Physician’s Recognition Award.
To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of the questions. 
A minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through July 31, 2004. 
The estimated time for completion of this activity is one hour and there is no fee for participation.
1. The rate of progression to cirrhosis in those with HCV is
increased in those who are co-infected with HIV.
a) True
b) False
2. Common laboratory abnormalities in those with end-stage liver
disease include:
a) Hypoalbuminemia
b) Prolonged INR
c) Elevated serum ammonia 
d) Thrombocytopenia
e) All of the above
3. The percentage of HCV-infected individuals in the US who
spend time in a prison or jail each year is closest to:
a) 5%
b) 15%
c) 30%
d) 50%
4. Approaches that may be efficacious for the treatment of variceal
bleeding include:
a) beta blockers, sclerotherapy, banding of varices
b) ace inhibitors, lactulose, low protein diets
c) beta blockers, low protein diets, paracentesis
5. Risk factors for acquiring methicillin-resistant St phylococcus
aureus(MRSA) include:
a) Injection drug use, recent surgery and hemodialysis
b) Diabetes, hemodialysis and HIV-infection
c) Spider bites, indwelling catheters or other hardware
d) None of the above
6. Antibiotics that may retain efficacy for the treatment of MRSA
include:
a) vancomycin, linezolid, ceftriaxone 
b) vancomycin, trimethoprim-sulfamethoxazole, linezolid
c) vancomycin, trimethoprim-sulfamethoxazole, ticarcillin
d) vancomycin, dicloxacillin, linezolid
BROWN MEDICAL SCHOOL •  OFFICE OF CONTINUING MEDICAL EDUCATION •  BOX G-A2  •  PROVIDENCE, RI 02912
The Brown Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME)to provide continuing medical 
education activities for physicians.  
The use of the Brown Medical School name implies review of the educational format and material only.  The opinions, recommendations 
and editorial positions expressed by those whose input is included in this bulletin are their own.  They do not represent or speak for the 
Brown Medical School.
For Continuing Medical Education credit please complete the following and mail or fax to 401.863.2660 or 
register online at www.hivcorrections.org. Be sure to print clearly so that we have the correct information for you.
Name __________________________________________________________________ Degree ____________________
Address ____________________________________________________________________________________________
____________________________________________________________________________________________________
City ____________________________________________________ State ________ Zip ________________________
Telephone ________________________________________________ Fax ______________________________________
HEPP Report Evaluation
5 Excellent    4 Very Good    3 Fair    2 Poor    1 Very Poor
1. Please evaluate the following sections with respect to:
educational value clarity
Main Article 5  4  3  2  1   5  4  3  2  1      
Inside News 5  4  3  2  1   5  4  3  2  1
Save the 
Dates 5  4  3  2  1   5  4  3  2  1
2. Do you feel that HEPP Report helps you in your work?
Why or why not?
3. What future topics should HEPP Report address?
4. How can HEPPReport be made more useful to you?
5. Do you have specific comments on this issue?
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